Spectrum Pharmaceuticals cancer news

Spectrum disclosed in an SEC filing that it received a subpoena in April from the SEC to produce documents related to the company's 2012 earnings announcement that it expected a "change in ordering patterns" of cancer drug Fusilev levoleucovorin. In March, the company lowered its...